ClinicalTrials.gg
CompletedNCT05129865Updated Nov 13, 2023

LYT-300 in Healthy Volunteers

A Phase 1/2 interventional study of LYT-300 and Placebo in Healthy Volunteers, sponsored by PureTech. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by PureTech · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Part 1 is a single ascending dose (SAD) trial in healthy volunteers (HV) to assess the safety, tolerability, and pharmacokinetic (PK) profile of orally administered LYT-300.

Part 2 is a crossover assessment in HV of the effects of food on the safety, tolerability, and PK profile of orally administered LYT-300.

Part 3 is a multiple ascending dose (MAD) trial in HV to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally administered LYT-300.

Part 4 is an assessment of the effects of LYT-300 vs. placebo on pharmacodynamic and patient reported outcome response to a validated clinical model of anxiety.

Read the detailed description

Part 1: This is a randomized, double-blind, placebo-controlled, SAD design to assess the safety, tolerability, and PK profile of orally administered LYT-300 in HV, in a 3-period, 3-sequence, crossover, dose escalation design.

Part 2: This is a randomized, open label, 3-period, 3-sequence, crossover assessment of the effects of food on the PK, safety, and tolerability of orally administered LYT-300 in HV. A single dose of LYT-300 will be administered on 3 occasions, separated by a minimum 7-day washout period. Part 2 is planned as a single dosing cohort.

Part 3: This is a randomized, double-blind, placebo-controlled, sequential, MAD trial in HV to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally administered LYT-300. This part will include ascending doses given either once daily in the morning (QAM), once daily in the evening (QHS), or twice daily (BID).

Part 4: This is a double-blind, randomized assessment of the effects in HV of a single dose of LYT-300 vs. placebo on pharmacodynamic and patient reported outcome response to a validated clinical model of anxiety.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

Parts 1, 2, 3 and 4: Healthy Volunteers

  1. Male or female between 18 and 55 years old (inclusive) at the time of screening.
  2. In good general health at screening, free from unstable medical, surgical or psychiatric illness, at the discretion of the Investigator.

Main Exclusion Criteria:

Parts 1, 2, 3 and 4: Healthy Volunteers

  1. Evidence or history of any condition or situation that adversely impacts a normal sleep-wake cycle.
  2. Confirmed COVID-19 infection within 2 months of screening, known exposure to another person with COVID-19 within 14 days of screening
  3. History of illness with fever within 28 days prior to the first dose.
  4. A history of, or current evidence for, serious mental illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    LYT-300 in healthy volunteers LYT-300, Doses TBD

    Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels

    Drug: LYT-300 · Other: Placebo

  • Experimental
    LYT-300 in healthy volunteers LYT-300

    LYT-300, Dose TBD with and without food, separated by 7-day washout

    Drug: LYT-300

  • Experimental
    LYT-300, Dose TBD QAM every 24 h for 7 days

    Drug: LYT-300

  • Placebo comparator
    Placebo QAM every 24 h for 7 days

    Other: Placebo

  • Placebo comparator
    Placebo QHS every 24 h for 7 days

    Drug: LYT-300 · Other: Placebo

  • Experimental
    LYT-300 in healthy volunteers LYT-300, Dose TBD QHS every 24 h for 7 days

    Drug: LYT-300 · Other: Placebo

  • Experimental
    LYT-300

    Drug: LYT-300

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugLYT-300

    A prodrug of allopregnanolone, a small molecule drug

  • OtherPlacebo

    Placebo for LYT-300

06

What researchers measure

Primary outcomes

  1. Safety and tolerability: treatment-emergent adverse events [TEAEs]

    Evaluate the safety and tolerability in healthy volunteers following single or multiple oral doses of LYT-300 as measured by TEAEs.

    Time frame: 7 days (main time frame)

  2. Effect of food in healthy volunteers

    Measure concentration of allopregnanolone in blood plasma in fed or fasted subjects administered a single dose of LYT-300

    Time frame: 2 days (main time frame)

  3. Salivary cortisol

    Change in salivary cortisol

    Time frame: 60 minutes

Secondary outcomes

  1. Use pharmacokinetics to characterize the blood plasma concentration of allopregnanolone after administration of LYT-300

    Measure the blood plasma concentrations of allopregnanolone in healthy volunteers after single and multiple doses of LYT-300 administered up to 7 days

    Time frame: 7 days (main time frame)

07

Study locations

1 site
  • CMAX
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Oct 2023, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2021
First posted
Nov 22, 2021
StartActual
Dec 7, 2021
Primary completionActual
Oct 18, 2023
CompletionActual
Oct 23, 2023
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05129865
Lead sponsor
PureTech
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Nov 22, 2021
Start date
Dec 7, 2021
Primary completion
Oct 18, 2023
Completion
Oct 23, 2023
Last update
Nov 13, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion